Replimune Group Beheer

Beheer criteriumcontroles 2/4

De CEO Replimune Group is Sush Patel, benoemd in Apr2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.074% van de aandelen van het bedrijf, ter waarde $ 751.70K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.2 jaar en 6.4 jaar.

Belangrijke informatie

Sush Patel

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	1.2yrs
Gemiddelde ambtstermijn bestuur	6.4yrs

Recente managementupdates

Recent updates

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Jun 24

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Apr 04

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Dec 16

Replimune: In The 'Buy Zone' Again

Oct 01

Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Sep 02

Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business

May 24

Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic

Apr 30

We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow

Feb 08

Replimune Group EPS misses by $0.03

Feb 04

Dosing underway in Replimune's early-stage cancer study with gene therapy

Jan 05

Analyse CEO-vergoeding

Hoe is Sush Patel's beloning veranderd ten opzichte van Replimune Group's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$213m
Jun 30 2024	n/a	n/a	-US$220m
Mar 31 2024	n/a	n/a	-US$216m
Dec 31 2023	n/a	n/a	-US$210m
Sep 30 2023	n/a	n/a	-US$199m
Jun 30 2023	n/a	n/a	-US$182m
Mar 31 2023	US$3m	US$447k	-US$174m
Dec 31 2022	n/a	n/a	-US$157m
Sep 30 2022	n/a	n/a	-US$147m
Jun 30 2022	n/a	n/a	-US$133m
Mar 31 2022	US$7m	US$394k	-US$118m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Sush redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de US markt.

Compensatie versus inkomsten: De vergoeding van Sush is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Sush Patel (53 yo)

less than a year

Tenure

US$2,595,003

Compensatie

Dr. Sushil Patel, also known as Sush,Ph D, is CEO & Director of Replimune Group, Inc. from April 1, 2024. Dr. Patel served as the Chief Commercial Officer at Replimune Group, Inc. since May 3, 2021 and ser...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Philip Astley-Sparke	Executive Chairman	9.8yrs	US$6.02m	1.86% $ 19.0m
Emily Hill	Chief Financial Officer	1.2yrs	US$3.61m	0.017% $ 177.5k
Konstantinos Xynos	Chief Medical Officer	1.9yrs	US$2.45m	0.017% $ 169.4k
Sushil Patel	CEO & Director	less than a year	US$2.60m	0.074% $ 751.7k
Robert Coffin	Founder	no data	US$5.72m	2.57% $ 26.2m
Andrew Schwendenman	Chief Accounting Officer & Treasurer	1.5yrs	geen gegevens	0.010% $ 104.8k
Christopher Sarchi	Chief Commercial Officer	1.9yrs	geen gegevens	0.017% $ 177.7k
Paul Bullock	Chief Manufacturing Officer & Framingham Site Head	less than a year	geen gegevens	geen gegevens

1.2yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van REPL wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Philip Astley-Sparke	Executive Chairman	9.8yrs	US$6.02m	1.86% $ 19.0m
Sushil Patel	CEO & Director	less than a year	US$2.60m	0.074% $ 751.7k
Robert Coffin	Founder	9.8yrs	US$5.72m	2.57% $ 26.2m
Joseph Slattery	Independent Director	7.1yrs	US$362.60k	0.0097% $ 99.5k
Hyam Levitsky	Independent Non-Executive Director	6.5yrs	US$355.10k	0% $ 0
Paolo Pucci	Independent Director	4.6yrs	US$360.10k	0% $ 0
Madhavan Balachandran	Director	less than a year	geen gegevens	geen gegevens
Kapil Dhingra	Independent Director	7.3yrs	US$357.60k	0% $ 0
Christy Oliger	Independent Director	2.9yrs	US$352.60k	0% $ 0
Dieter Weinand	Lead Independent Director	6.4yrs	US$516.81k	0% $ 0
Veleka Peeples-Dyer	Independent Director	1.4yrs	US$667.97k	0% $ 0

6.4yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van REPL wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.4 jaar).

Replimune Group Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Chief Financial Officer recently sold US$91k worth of stock

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Chief Medical Officer notifies of intention to sell stock

Executive Chairman recently sold US$245k worth of stock

Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024

Chief Medical Officer recently sold US$80k worth of stock

Recent updates

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

New minor risk - Share price stability

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune: Strong Data In A Highly Differentiated Space

Chief Financial Officer recently sold US$91k worth of stock

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Consensus revenue estimates decrease by 50%, EPS upgraded

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Price target increased by 8.2% to US$14.67

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Chief Medical Officer notifies of intention to sell stock

Price target increased by 9.2% to US$14.56

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

New minor risk - Share price stability

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Replimune: Continuing To Justify The Bear Thesis (For Now)

Executive Chairman recently sold US$245k worth of stock

Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Now 25% undervalued after recent price drop

Price target decreased by 64% to US$17.22

New minor risk - Share price stability

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Chief Medical Officer recently sold US$80k worth of stock

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

New major risk - Revenue and earnings growth

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Chief Business Officer exercised options and sold US$250k worth of stock

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Chief Business Officer notifies of intention to sell stock

Chief Strategy Officer notifies of intention to sell stock

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates fall by 42%

CEO & Director recently sold US$323k worth of stock

No longer forecast to breakeven

Insufficient new directors

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Replimune Group, Inc. Announces Executive Appointments

Chief Business Officer exercised options and sold US$360k worth of stock

Price target increased to US$48.89

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune secures $200M term loan

Replimune: Recent Developments Strengthen Bull Thesis

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune Group GAAP EPS of -$0.78 misses by $0.15

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold US$156k worth of stock

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Replimune Group, Inc. Announces Updated Data from Completed Cohorts of the Phase 2 Part of the IGNYTE Clinical Trial in Non-Melanoma Skin Cancer (Nmsc) and Melanoma

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Chief Operating Officer notifies of intention to sell stock

Replimune: In The 'Buy Zone' Again